USFDA grants tentative approval to Lupin’s generic formulation for type 2 diabetes
时间:2024-06-26 16:51:40 阅读(143)
Global pharma major Lupin Limited on Friday announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Dapagliflozin and Saxagliptin Tablets, 5 mg/5 mg and 10 mg/5 mg.
According to the company’s press statement, the approval has been granted to market a generic equivalent of Qtern Tablets, 5 mg/5 mg and 10 mg/5 mg of AstraZeneca AB. This product will be manufactured at Lupin’s Pithampur facility in India.
Dapagliflozin and Saxagliptin Tablets (RLD Qtern) had estimated annual sales of USD 5 million in the U.S. (IQVIA MAT November 2023).
上一篇:F&O outlook- Nifty may head to 17300, look for buying opportunities until short formations emerge
下一篇:Zomato told to cough up Rupees 401 crore as GST on delivery charges
猜你喜欢
- Rupee settles on flat note at 82
- Gold Price Today, 14 Jun 2022- Gold prices fall on weak global cues ahead of US Fed meet; support at Rs 50,000
- Rupee recovers 6 paise to settle at 82
- Samsung’s Galaxy S24 series to copy this Google Pixel 8 Pro AI feature; launch pegged for January 17
- Gold Price Today, 10 May- Gold price falls, trades in a tight range; traders await US CPI number
- Going slow on the D-word- The next government must push disinvestments in next fiscal
- FII DII data- FPI sold shares worth Rs 212
- Fall in freight to keep Russian oil in demand
- FDI inflows to ‘rebound’ in coming months- MoF